SWOG clinical trial number
CTSU/EA8153

Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Closed
Phase
Abbreviated Title
Rando Exten Dis Cabazitaxel w/ Abi vs. Abi following Docetaxel- CHAARTED2
Status Notes
This study is permanently closed effective 4/2/2021.
Activated
02/08/2018

Research committees

Genitourinary Cancer

Treatment

Prednisone Abiraterone Acetate Cabazitaxel

Publication Information Expand/Collapse

2024

Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153)

C Kyriakopoulos;Y Chen;R Jeraj;F Duan;J Luo;E Antonarakis;A Tripathi;D Kosoff;R Garje;R Pachynski;R Parikh;A Harzstark;N Adra;B Maughan;Y Zakharia;P Corn;G Liu;M Carducci ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), LBA, Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 17; abstr LBA5000)

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase